论文部分内容阅读
观察肿瘤患者血清可溶性白细胞介素 2受体 (s IL- 2 R)水平的变化及临床意义。方法 :采用双抗体夹心 EL ISA法对 40例正常人、 30例良性肿瘤及 180例恶性肿瘤患者的血清 s IL- 2 R水平进行测定。结果 :1正常人和良性肿瘤患者血清 s IL-2 R水平较低 ,恶性肿瘤患者明显升高 ,与正常人及良性肿瘤患者比较均有极显著性差异 (P <0 .0 0 1) ;2 s IL- 2 R水平与临床分期及病情严重程度有关 ,处于 、 期的肿瘤患者血清 s IL- 2 R水平显著高于 、 期肿瘤患者 (P <0 .0 1) ;3 6 5例恶性肿瘤患者经手术切除及综合治疗后血清 s IL- 2 R水平较术前明显下降 (P <0 .0 5 )。结论 :恶性肿瘤患者血清 s IL- 2 R水平明显高于正常人及良性肿瘤患者 ,并与病情发展和转归密切相关。
To observe the changes of serum soluble interleukin 2 receptor (sIL-2 R) level and its clinical significance in cancer patients. Methods: The levels of serum IL-2R in 40 normal subjects, 30 benign tumors and 180 malignant tumors were measured by double-antibody sandwich ELISA. Results: Serum levels of IL-2R were significantly lower in patients with normal and benign tumors than those in patients with benign and malignant tumors (P <0.01). The level of IL-2R was correlated with the clinical stage and the severity of the disease. Serum IL-2R level was significantly higher in patients with cancer than in patients with advanced cancer (P <0.01); 365 patients with malignant The level of serum sIL-2R in patients with tumor was significantly lower than that before operation after surgical resection and comprehensive treatment (P <0.05). Conclusion: The level of serum sIL-2R in patients with malignant tumor is significantly higher than that in normal people and benign tumor, which is closely related to the development and prognosis of patients.